BPC-157: Clinical Guide for Prescribing Practices
BPC-157 is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It has been studied for its effects on tissue repair, gut healing, musculoskeletal recovery, and inflammation reduction. It is one of the most widely requested peptides in clinical practice settings.
Also Known As
How BPC-157 Works
BPC-157 promotes angiogenesis via upregulation of VEGF and stimulates the FAK-paxillin signaling pathway, accelerating tendon and ligament fibroblast migration [1]. It also modulates the nitric oxide (NO) system and interacts with the dopaminergic system, contributing to cytoprotective and anti-inflammatory effects across multiple tissue types [2].
Clinical Evidence
A 2021 systematic review identified over 100 preclinical studies demonstrating efficacy in tendon, ligament, muscle, and GI mucosal healing models [1]. No randomized controlled human trials have been completed to date. The consistency of animal model results across multiple independent research groups supports biological plausibility, though the absence of human data remains a significant limitation. FDA compounding category status should be verified prior to prescribing [4].
Clinical Uses
Patient Selection and Screening
Best suited for patients with chronic musculoskeletal injuries unresponsive to conventional therapy, post-surgical tissue healing protocols, and GI mucosal repair (e.g., NSAID gastropathy, inflammatory bowel conditions) [2]. Ideal candidates are those who have failed conservative management and seek to avoid or delay surgical intervention.
Dosing and Administration
Subcutaneous dosing typically ranges from 250 to 500 mcg once or twice daily, with treatment courses of 4 to 6 weeks [1]. Injection site should be rotated and selected proximal to the injury when possible. Oral capsule dosing (for GI indications) is typically 500 mcg twice daily on an empty stomach [2]. Protocols may be repeated after a washout period of 2 to 4 weeks.
Route: Subcutaneous injection, oral capsule
Protocol notes: Typically administered via subcutaneous injection. Dosing and duration vary by clinical indication and physician judgment.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
BPC-157 is among the highest-demand peptides in regenerative medicine practices, often serving as an entry point for patients new to peptide therapy. Average wholesale cost per vial supports strong margins, and the typical 4 to 6 week treatment course drives recurring revenue. Practices offering BPC-157 report high patient satisfaction and retention rates due to rapid symptomatic improvement in musculoskeletal complaints.
FDA Category Status
Expected to return to Category 1 per February 2026 HHS announcement
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe BPC-157 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
Is BPC-157 FDA approved?
What evidence supports BPC-157 for tissue repair?
Which compounding pharmacies carry BPC-157?
References
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors: A Systematic Review. Life (Basel). 2021;11(9):907.
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157. Curr Neuropharmacol. 2016;14(8):857-865.
- Vukojevic J, et al. Rat Inferior Caval Vein (ICV) Ligature and Pentadecapeptide BPC 157. Vasc Pharmacol. 2018;106:46-56.
- FDA Bulk Drug Substances Advisory: Compounding Category Updates (2024)
Related Peptides in Tissue Repair & Recovery
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe BPC-157 Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe BPC-157 Through Karpa